Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.

IF 4.6 2区医学 Q1 CLINICAL NEUROLOGY Journal of Neurology Pub Date : 2025-01-23 DOI:10.1007/s00415-024-12882-4

Vasileios Giannopapas, Vassiliki Smyrni, Dimitrios K Kitsos, Maria Ioanna Stefanou, Aikaterini Theodorou, John S Tzartos, Georgios Tsivgoulis, Sotirios Giannopoulos

{"title":"Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.","authors":"Vasileios Giannopapas, Vassiliki Smyrni, Dimitrios K Kitsos, Maria Ioanna Stefanou, Aikaterini Theodorou, John S Tzartos, Georgios Tsivgoulis, Sotirios Giannopoulos","doi":"10.1007/s00415-024-12882-4","DOIUrl":null,"url":null,"abstract":"Introduction: The current literature on the prevalence and potential association between disease-modifying therapies (DMTs) and cancer risk in the MS population has yielded mixed findings.Methods: This study aimed to estimate cancer prevalence and cancer risk in patients with MS (PwMS) under prolonged DMT exposure. Database search include: MEDLINE PUBMED, SCOPUS, and Google Scholar.Results: A total of 13 studies involving 333,779 PwMS were included, reporting cancer events over periods ranging from 6 to 32 years. The aggregated pooled prevalence of cancer events in MS patients receiving disease-modifying therapies (DMTs) was 3.8% (95% CI 2.6, 5.2%), with substantial heterogeneity (I2 = 99.7%, p = 0). Two studies compared cancer events in MS patients who received DMTs versus those who did not. The relative risk of cancer associated with DMTs was 0.8 (95% CI 0.59-1.31, I2 = 93.6%, p = 0.53), indicating no significant increase in cancer risk due to DMTs. Breast and basal cell carcinomas had a high prevalence (18.4% and 11.3, respectively) in PwMS under DMTs.Conclusion: This study reports a 3.8% pooled prevalence of cancer in PwMS receiving DMTs. The findings of this study suggest that DMTs alone do not increase cancer risk in PwMS. Breast cancer and basal cell carcinoma had the highest prevalence among the different types of cancer.","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 2","pages":"162"},"PeriodicalIF":4.6000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757934/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00415-024-12882-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The current literature on the prevalence and potential association between disease-modifying therapies (DMTs) and cancer risk in the MS population has yielded mixed findings.

Methods: This study aimed to estimate cancer prevalence and cancer risk in patients with MS (PwMS) under prolonged DMT exposure. Database search include: MEDLINE PUBMED, SCOPUS, and Google Scholar.

Results: A total of 13 studies involving 333,779 PwMS were included, reporting cancer events over periods ranging from 6 to 32 years. The aggregated pooled prevalence of cancer events in MS patients receiving disease-modifying therapies (DMTs) was 3.8% (95% CI 2.6, 5.2%), with substantial heterogeneity (I² = 99.7%, p = 0). Two studies compared cancer events in MS patients who received DMTs versus those who did not. The relative risk of cancer associated with DMTs was 0.8 (95% CI 0.59-1.31, I² = 93.6%, p = 0.53), indicating no significant increase in cancer risk due to DMTs. Breast and basal cell carcinomas had a high prevalence (18.4% and 11.3, respectively) in PwMS under DMTs.

Conclusion: This study reports a 3.8% pooled prevalence of cancer in PwMS receiving DMTs. The findings of this study suggest that DMTs alone do not increase cancer risk in PwMS. Breast cancer and basal cell carcinoma had the highest prevalence among the different types of cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

长期接受疾病改善疗法（dmt）后多发性硬化症患者的癌症：一项系统回顾和荟萃分析

目前关于MS人群中疾病修饰疗法（dmt）与癌症风险之间的患病率和潜在关联的文献得出了不同的结果。方法：本研究旨在评估长期接触DMT的多发性硬化症（PwMS）患者的癌症患病率和癌症风险。数据库搜索包括：MEDLINE PUBMED， SCOPUS，谷歌Scholar。结果：共纳入13项研究，涉及333,779名PwMS，报告了6至32年期间的癌症事件。接受疾病改善治疗（dmt）的MS患者中癌症事件的总发生率为3.8% (95% CI 2.6, 5.2%)，存在很大的异质性（I2 = 99.7%, p = 0）。两项研究比较了接受dmt治疗和未接受dmt治疗的多发性硬化症患者的癌症事件。与dmt相关的癌症相对风险为0.8 (95% CI 0.59-1.31, I2 = 93.6%, p = 0.53)，表明dmt没有显著增加癌症风险。乳腺癌和基底细胞癌在DMTs下的PwMS中有很高的患病率（分别为18.4%和11.3）。结论：本研究报告了接受dmt治疗的PwMS患者的癌症总患病率为3.8%。这项研究的结果表明，单独的dmt不会增加PwMS的癌症风险。在不同类型的癌症中，乳腺癌和基底细胞癌的患病率最高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Neurology 医学-临床神经学

CiteScore

10.00

自引率

5.00%

发文量

558

审稿时长

1 months

期刊介绍： The Journal of Neurology is an international peer-reviewed journal which provides a source for publishing original communications and reviews on clinical neurology covering the whole field. In addition, Letters to the Editors serve as a forum for clinical cases and the exchange of ideas which highlight important new findings. A section on Neurological progress serves to summarise the major findings in certain fields of neurology. Commentaries on new developments in clinical neuroscience, which may be commissioned or submitted, are published as editorials. Every neurologist interested in the current diagnosis and treatment of neurological disorders needs access to the information contained in this valuable journal.